electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21
electroCore (Nasdaq: ECOR), a bioelectronic medicine and wellness company, announced its participation in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21, 2024 in New York City.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
electroCore (Nasdaq: ECOR), a bioelectronic medicine and wellness company, announced its participation in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21, 2024 in New York City. Joshua Lev, Chief Financial Officer, will be available for one-on-one meetings throughout the event. Interested investors can arrange meetings through their Canaccord Genuity representatives.
Details
News Market Reaction – ECOR
The recorded move for ECOR in the trading session of this news was +1.49%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKAWAY, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum taking place in New York City on November 21, 2024.
Joshua Lev, Chief Financial Officer, will host one-on-one meetings throughout the day.
To schedule a one-on-one meeting with Mr. Lev, investors are encouraged to reach out to their CG representative. For more information regarding the event please visit https://www.meetmax.com/sched/event_110807/conference_home.html.
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
Contact
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.